Full Press Release Details
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform.
ZYME
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Key Takeaway: Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
Price reaction · baseline $27.2 (2026-04-16 close) · hit after-hours · 1 other ZYME headline(s) in the window, move may be shared
day 0 close
+2.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+25%
120-day peak, hindsight
Typical move
4.8%
average across 15 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers